Medical Devices - Cardiac Surgery/Electrophysiology
Strategic Profile
AtriCure's AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. Accelerated adoption of innovative minimally invasive devices and successful product launches are driving strong revenue growth, profitability, and operating leverage, with global market expansion, advancing clinical trials, and robust evidence generation broadening access and supporting payer acceptance.
Cyborg Score Rationale
In 2024, AtriCure's revenue was $465.31 million, an increase of 16.55% compared to the previous year's $399.25 million. According to 9 analysts, the average rating for ATRC stock is Strong Buy. The company shows solid growth trajectory with market leadership in key device categories.
Top Insights
Market-leading position in LAA management devices with global penetration across US, Europe, and Asia-Pacific regions
Consistent double-digit revenue growth (16.5% in 2024) driven by device adoption and product expansion including cryoXT for post-operative pain
Strong analyst consensus with 9 analysts rating as Strong Buy and $52 12-month price target implying 47% upside
Expanding product pipeline and clinical evidence supporting broader surgical adoption across persistent atrial fibrillation indications
Named Competitors
Catheter-based ablation systems — Electrophysiology catheter-based AF treatment alternatives
Drug-based AF management — Anti-arrhythmic medications as alternative to surgical intervention
LAA exclusion devices — Percutaneous left atrial appendage closure alternatives
Recent Developments
(Dec 2025) Launched cryoXT device for post-operative pain management following amputation, expanding pain management market opportunity
(Dec 2025) Introduced technology combining Pulsed Field Ablation and Advanced Radiofrequency Ablation with EnCompass clamp to reduce treatment time
(Feb 2025) Reported Q4 2024 revenue of $124.3 million, up 16.6% YoY, with CEO optimistic outlook for Analyst Day in March
Open the full interactive AtriCure, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.